Your browser doesn't support javascript.
loading
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan, Seyed; Zhao, Ming; Yuca, Erkan; Annis, Allen; Evans, Kurt; Sutton, David; Carvajal, Luis; Ren, Jian-Guo; Santiago, Solimar; Guerlavais, Vincent; Akcakanat, Argun; Tapia, Coya; Yang, Fei; Bose, Priya Subash Chandra; Zheng, Xiaofeng; Dumbrava, Ecaterina Ileana; Aivado, Manuel; Meric-Bernstam, Funda.
Afiliação
  • Pairawan S; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhao M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
  • Yuca E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
  • Annis A; Aileron Therapeutics, Cambridge, MA, USA.
  • Evans K; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
  • Sutton D; Aileron Therapeutics, Cambridge, MA, USA.
  • Carvajal L; Aileron Therapeutics, Cambridge, MA, USA.
  • Ren JG; Aileron Therapeutics, Cambridge, MA, USA.
  • Santiago S; Aileron Therapeutics, Cambridge, MA, USA.
  • Guerlavais V; Aileron Therapeutics, Cambridge, MA, USA.
  • Akcakanat A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
  • Tapia C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yang F; Present address: Epizyme Inc., Cambridge, MA, USA.
  • Bose PSC; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zheng X; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dumbrava EI; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Aivado M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
  • Meric-Bernstam F; Aileron Therapeutics, Cambridge, MA, USA.
Breast Cancer Res ; 23(1): 29, 2021 03 04.
Article em En | MEDLINE | ID: mdl-33663585
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas / Proteínas de Ciclo Celular / Inibidores de Proteínas Quinases / Proteínas Proto-Oncogênicas c-mdm2 Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas / Proteínas de Ciclo Celular / Inibidores de Proteínas Quinases / Proteínas Proto-Oncogênicas c-mdm2 Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article